{"references": ["Vol. 2008 N3; CD005390. 2008. Figueredo A, Coombes M.E and Mukherjee S. Adjuvant Therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. Doi: https://doi.org/10.1002/14651858.cd005390.pub2", "Vol. 12 N9; p\u00e1gs. 2584. 2020. Rebuzzi SE, Pesola G, Martelli V, Sobrero AF. Adjuvant Chemotherapy for Stage II Colon Cancer. Cancers (Basel). Doi: https://doi.org/10.3390%2Fcancers12092584", "Vol. 31 N10; p\u00e1gs. 1291-1305. 2020. Argil\u00e9s G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. Doi: https://doi.org/10.1016/j.annonc.2020.06.022", "Vol. 5; N8; p\u00e1gs. 1124-1131. 2019. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology. Doi: https://doi.org/10.1001/jamaoncol.2019.0528", "Vol. 17; N12; p\u00e1gs. 757-770. 2020. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and RectalAnal Task Forces whitepaper. Nature Reviews Clinical Oncology. Doi: https://doi.org/10.1038/s41571-020-0392-0", "Vol. 8; N346; p\u00e1gs. 346ra92. 2016. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine. Doi: https://doi.org/10.1126/scitranslmed.aaf6219", "Vol. 39; N6; p\u00e1gs. 631-641. 2021. Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, et al. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology. Doi: https://doi.org/10.1200/jco.20.01330"]}

La quimioterapia adyuvante (QA) en el cáncer de colon estadio II resecado sigue siendo controvertida. Actualmente se emplea en aquellos pacientes con factores clínicos o patológicos de riesgo añadidos. La detección de DNA tumoral circulante (ctDNA) en biopsia líquida se ha estudiado como potencial factor pronóstico en este escenario. Es interesante su implementación para ayudar en la toma de decisiones terapéuticas. Adjuvant chemotherapy (AQ) in resected stage II colon cancer remains controversial and is currently used in patients with added clinical or pathological risk factors. Positive circulating tumour DNA (ctDNA) in liquid biopsy has been studied as a potential prognostic factor in this scenario, so can be useful tool in therapeutic decision-making.